Neurocrine Biosciences — Third Quarter 2026 Earnings Summary

Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.123 billion, representing a 41% year-over-year increase driven by strong sales of its core products. INGREZZA net product sales reached $801 million, while CRENESSITY and VYKAT XR contributed $211 million and $107 million, respectively. The company raised its full-year 2026 net product sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion. GAAP net income for the quarter was $206.5 million, while non-GAAP net income was $346.7 million, reflecting adjustments for stock-based compensation and acquisition-related costs.